Form 4 for RLAY Relay Therapeutics, Inc.

Accepted 2023-01-19 00:00:00 ET · period of report 2023-01-17 · accession 0001209191-23-004123 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-01-19	2023-01-17	RLAY	Adams Brian	CLO	A - Grant	$0.00	+85.4K	137.0K	+166%	$0
DM	2023-01-19	2023-01-17	RLAY	Adams Brian	CLO	A - Grant	$0.00	+170.8K	73.2K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-01-17	A	A	85,425	$0.00	136,956	D	—	—	(F1) Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. (F2) Includes 126,259 shares underlying RSUs.
2	Derivative	Stock Option (Right to Buy)	2023-01-17	A	A	97,630	$0.00	97,630	D	$20.45 · — to 2033-01-16	97,630 Common Stock	(F3) The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 17, 2023, subject to the reporting person's continued service with the Issuer through each vesting date.
3	Derivative	Stock Option (Right to Buy)	2023-01-17	A	A	73,220	$0.00	73,220	D	$20.45 · — to 2033-01-16	73,220 Common Stock	(F4) Such option was granted pursuant to the terms of the Issuer's 2020 Stock Option and Incentive Plan and becomes exercisable, if at all, in twelve equal quarterly installments if the last quoted trading price per share of the Issuer's common stock on the Nasdaq Global Market during any fifteen consecutive calendar day period is at least $35.00; provided that the reporting person maintains a service relationship with the Issuer.